Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
Key disclosure: On 24 June 2025 Point72 Asset Management, Point72 Capital Advisors and founder Steven A. Cohen jointly filed a Schedule 13G regarding Amylyx Pharmaceuticals, Inc. (AMLX).
The filing shows 4,717,709 AMLX common shares held through Point72 Associates, equivalent to 5.3 % of the company’s outstanding stock. All voting and dispositive authority is listed as “shared,” with zero sole power reported. The report is passive, made under Rule 13d-1(b), and classifies the reporting persons as: Point72 Asset Management – “PN” (Partnership), Point72 Capital Advisors – “CO” (Corporation), and Mr. Cohen – “IN” (Individual).
Ownership is indirect: Point72 Asset Management manages the securities, Point72 Capital Advisors is its general partner, and Mr. Cohen controls both entities. The principal business address for all parties is 72 Cummings Point Road, Stamford, CT 06902. A joint-filing agreement (Exhibit 99.1) formalises combined reporting.
This disclosure elevates Point72 to the roster of ≥5 % institutional holders of Amylyx, giving the hedge fund material visibility in the share register; however, the filing contains no purchase prices, transaction timetables, or stated strategic intentions beyond passive investment.